Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
Author:
Funder
Massachusetts General Hospital
National Institutes of Health
National Cancer Institute
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference13 articles.
1. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov,2016
2. Targeting ALK: precision medicine takes on drug resistance;Lin;Cancer Discov,2017
3. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer;Dagogo-Jack;Clin Cancer Res,2020
4. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer;Shiba-Ishii;Nat Cancer,2022
5. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial;Camidge;J Thorac Oncol,2021
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23
2. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23
3. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02
4. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver;Lung Cancer: Targets and Therapy;2024-02
5. Current opportunities and challenges in ALK-positive lung cancer;Translational Lung Cancer Research;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3